Congratulations on the successful implementation of new equipment in the Nuclear Medicine Department of Heyi First Affiliated Hospital! The new nuclide residue measuring instrument can not only more accurately control the safety threshold of nuclide residue when patients are discharged, reduce potential radiation risks to the public and the environment, but also improve the efficiency of departmental discharge assessment, making patients and medical staff more at ease.

The measurement of residual nuclides in the body of patients in nuclear medicine is carried out through specialized instruments to detect non metabolites in the patient's bodyfinishThe DF-Nu503A nuclide therapy monitoring system from Beijing Dongfang Yuantong is indeed a very high-performance device, which is a key step in determining whether the radioactive nuclide activity meets discharge safety standards or evaluating treatment efficacy.

The system consists of a radionuclide therapy monitor and monitoring software, mainly used to measure residual drug activity in patients undergoing radionuclide therapy and assist hospitals in patient discharge control. It is equipped with a highly sensitive scintillation detector that can quickly and accurately measure the activity of iodine-131 in the patient's body over a wide range of activities, providing reliable data support for doctors to determine the residual drug situation in the patient's body. At the same time, the system is also equipped with video surveillance and voice communication functions, which can monitor the patient testing process in real time and improve the safety and standardization of the testing process. In addition, the test data is transmitted to the radionuclide therapy monitoring software via Ethernet, which automatically detects residual activity in the patient's body. When the activity is within the specified value, the patient can be discharged, achieving automation and efficiency in data processing and discharge determination.